Skip to main content
Top
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer

Authors: You-Jin Lu, Rong-Yu Liu, Kun Hu, Ying Wang

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

Lung cancer remains a leading cause of cancer-associated mortality worldwide, and non-small lung cancer (NSCLC) is responsible for over 80 % of lung cancer-related deaths. Identifying novel molecular biomarker that can inhibit the progression of lung cancer will facilitate the development of new treatment strategies. Herein, we demonstrated that miR-541-3p is a tumor-suppressor microRNA (miRNA) in NSCLC progression. We found that expression of miR-541-3p was decreased obviously in NSCLC tissues and plasma. Down-regulation of miR-541-3p was associated with TNM stage and postoperative survival. Overexpression of miR-541-3p inhibited the growth and metastasis of NSCLC cells. The TGIF2 was a direct target of miR-541-3p and promoted the growth and metastasis of NSCLC cells. Further study showed that TGIF2 could reverse the inhibitory effect of miR-541-3p on growth and metastasis of NSCLC cells. Taken together, our data highlight the pivotal role of miR-541-3p in the progression of NSCLC. Thus, miR-541-3p may be a potential prognostic marker and of treatment relevance for NSCLC progression intervention.
Literature
3.
go back to reference Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44. doi:10.1200/JCO.2005.04.4859.CrossRefPubMed Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44. doi:10.​1200/​JCO.​2005.​04.​4859.CrossRefPubMed
4.
go back to reference Song YJ, Wang LX, Hong YQ, Lu ZH, Tong Q, Fang XZ, et al. Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. Tumour Biol. 2015. doi:10.1007/s13277-015-4397-8. Song YJ, Wang LX, Hong YQ, Lu ZH, Tong Q, Fang XZ, et al. Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. Tumour Biol. 2015. doi:10.​1007/​s13277-015-4397-8.
8.
go back to reference Sun Y, Chen C, Zhang P, Xie H, Hou L, Hui Z, et al. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep. 2014;4:6527. doi:10.1038/srep06527.CrossRefPubMed Sun Y, Chen C, Zhang P, Xie H, Hou L, Hui Z, et al. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep. 2014;4:6527. doi:10.​1038/​srep06527.CrossRefPubMed
12.
go back to reference Imoto I, Pimkhaokham A, Watanabe T, Saito-Ohara F, Soeda E, Inazawa J. Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. Biochem Biophys Res Commun. 2000;276(1):264–70. doi:10.1006/bbrc.2000.3449.CrossRefPubMed Imoto I, Pimkhaokham A, Watanabe T, Saito-Ohara F, Soeda E, Inazawa J. Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. Biochem Biophys Res Commun. 2000;276(1):264–70. doi:10.​1006/​bbrc.​2000.​3449.CrossRefPubMed
13.
go back to reference Wang Y, Wang CM, Jiang ZZ, Yu XJ, Fan CG, Xu FF, et al. MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2015;10(5):3095–102. doi:10.3892/ol.2015.3649.PubMedPubMedCentral Wang Y, Wang CM, Jiang ZZ, Yu XJ, Fan CG, Xu FF, et al. MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2015;10(5):3095–102. doi:10.​3892/​ol.​2015.​3649.PubMedPubMedCentral
14.
go back to reference Tian Y, Wei W, Li L, Yang R. Down-regulation of miR-148a promotes metastasis by DNA methylation and is associated with prognosis of skin cancer by targeting TGIF2. Med Sci Monit. 2015;21:3798–805.CrossRefPubMedPubMedCentral Tian Y, Wei W, Li L, Yang R. Down-regulation of miR-148a promotes metastasis by DNA methylation and is associated with prognosis of skin cancer by targeting TGIF2. Med Sci Monit. 2015;21:3798–805.CrossRefPubMedPubMedCentral
15.
go back to reference Hu Y, Pu Q, Cui B, Lin J. MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting TGIF2. Int J Clin Exp Pathol. 2015;8(8):8921–8.PubMedPubMedCentral Hu Y, Pu Q, Cui B, Lin J. MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting TGIF2. Int J Clin Exp Pathol. 2015;8(8):8921–8.PubMedPubMedCentral
17.
go back to reference Sun H, Pan Y, He B, Deng Q, Li R, Xu Y, et al. Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting. Int J Oncol. 2015;46(4):1759–67. doi:10.3892/ijo.2015.2852.PubMed Sun H, Pan Y, He B, Deng Q, Li R, Xu Y, et al. Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting. Int J Oncol. 2015;46(4):1759–67. doi:10.​3892/​ijo.​2015.​2852.PubMed
21.
go back to reference Lee J, Warnken U, Schnolzer M, Gebert J, Kopitz J. A new method for detection of tumor driver-dependent changes of protein sialylation in a colon cancer cell line reveals nectin-3 as TGFBR2 target. Protein Sci. 2015;24(10):1686–94. doi:10.1002/pro.2741.CrossRefPubMedPubMedCentral Lee J, Warnken U, Schnolzer M, Gebert J, Kopitz J. A new method for detection of tumor driver-dependent changes of protein sialylation in a colon cancer cell line reveals nectin-3 as TGFBR2 target. Protein Sci. 2015;24(10):1686–94. doi:10.​1002/​pro.​2741.CrossRefPubMedPubMedCentral
22.
go back to reference Quiles F, Menendez M, Tornero E, Del Valle J, Teule A, Palanca S, et al. Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA. Breast Cancer Res Treat. 2016;155(2):253–60. doi:10.1007/s10549-015-3676-9.CrossRefPubMed Quiles F, Menendez M, Tornero E, Del Valle J, Teule A, Palanca S, et al. Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA. Breast Cancer Res Treat. 2016;155(2):253–60. doi:10.​1007/​s10549-015-3676-9.CrossRefPubMed
24.
go back to reference Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, et al. MiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and TGIF2. Nature. 2014;512(7515):431–5. doi:10.1038/nature13375.CrossRefPubMed Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, et al. MiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and TGIF2. Nature. 2014;512(7515):431–5. doi:10.​1038/​nature13375.CrossRefPubMed
Metadata
Title
MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer
Authors
You-Jin Lu
Rong-Yu Liu
Kun Hu
Ying Wang
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5241-5

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine